光正眼科医院集团股份有限公司 证券代码：002524 证券简称：光正眼科 公告编号：2023-076 光正眼科医院集团股份有限公司 关于 2023 年限制性股票激励计划内幕信息知情人 及激励对象买卖公司股票的自查报告 责任公司深圳分公司出具了书面的查询结果。 二、核查对象买卖公司股票的情况说明 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 光正眼科医院集团股份有限公司（以下简称"公司"）于 2023 年 8 月 23 日 召开第五届董事会第十九次会议和第五届监事会第十五次会议审议通过了《关于 公司<2023 年限制性股票激励计划（草案）>及摘要的议案》等相关议案，具体 内容详见公司于 2023 年 8 月 25 日在巨潮资讯网（http://www.cninfo.com.cn） 等指定信息披露媒体的相关公告。 根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）、《深 圳证券交易所上市公司自律监管指南第 1 号——业务办理》（以下简称"《自律 监管指南》"）等相关法律、法规及规范性文件的规定，公司对 2023 年限制性 股票激励计划（以下简称"本次激 ...

光正眼科医院集团股份有限公司 证券代码：002524 证券简称：光正眼科 公告编号：2023-075 光正眼科医院集团股份有限公司 2023 年度第三次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东大会没有被否决议案的情形，没有增加或变更提案。 2.本次股东大会不涉及变更前次股东大会决议。 一、 会议召开情况 1.会议召开的日期、时间： 现场会议时间为：2023 年 9 月 11 日（星期一）下午 15:00； 网络投票时间为：2023 年 9 月 11 日。其中：通过深圳证券交易所交易系统 进行网络投票的具体时间为2023年9月11日9:15—9:25,9:30—11:30 和13:00 —15:00；通过深圳证券交易所互联网投票系统投票的具体时间为 2023 年 9 月 11 日 9:15—15:00 期间的任意时间。 2.现场会议召开地点：光正眼科医院集团股份有限公司会议室（乌鲁木齐经 济技术开发区融合北路 266 号）； 3.会议的召开方式：本次股东大会采取现场投票与网络投票相结合的方式； 本次股东大会按 ...

关于光正眼科医院集团股份有限公司 2023 年度第三次临时股东大会 法律意见书 天阳证股字[2023]第 33 号 新疆天阳律师事务所 二○二三年九月 1 T&P 新疆天阳律师事务所 光正眼科 2023 年度第三次临时股东大会 新疆天阳律师事务所 T&P 新疆天阳律师事务所 光正眼科 2023 年度第三次临时股东大会 新疆天阳律师事务所 关于光正眼科医院集团股份有限公司 2023 年度第三次临时股东大会 法律意见书 天阳证股字[2023]第 33 号 致：光正眼科医院集团股份有限公司 新疆天阳律师事务所（下称"本所"）接受光正眼科医院集团股份有限公司 （下称"公司"）的委托，委派本所常娜娜律师、康晨律师出席公司 2023 年度第 三次临时股东大会，根据《中华人民共和国公司法》（下称"《公司法》"）、《中华 人民共和国证券法》（下称"《证券法》"）、《上市公司股东大会规则》和《光正眼 科医院集团股份有限公司章程》（下称"《公司章程》"），按照律师行业公认的业 务标准、道德规范和勤勉尽责精神，对有关的文件和事实进行核查与验证，现出 具法律意见如下： 一、本次临时股东大会的召集、召开程序 1．公司董事会于 2023 ...

T&P 新疆天阳律师事务所 光正眼科独立董事公开征集委托投票权相关事项之法律意见书 新疆天阳律师事务所 关于 法律意见书 天阳证专字[2023]第 17 号 乌鲁木齐市水磨沟区红光山路 888 号绿城广场写字楼 2A 座 7 层 邮编：830002 电话（0991）3550178 传真：（0991）3550219 1 光正眼科医院集团股份有限公司 独立董事公开征集委托投票权相关事项 之 T&P 新疆天阳律师事务所 光正眼科独立董事公开征集委托投票权相关事项之法律意见书 新疆天阳律师事务所关于光正眼科医院集团股份有限公司 独立董事公开征集委托投票权相关事项之法律意见书 天阳证发字[2023]第 17 号 致：光正眼科医院集团股份有限公司 T&P 新疆天阳律师事务所 光正眼科独立董事公开征集委托投票权相关事项之法律意见书 民事行为能力，并且其签署行为已获得恰当、有效的授权；所有文件或资料上的 签字和印章均为真实。 四、本所及经办律师仅对本次征集投票权的相关事项的合法性、合规性发表 意见，对于其他问题本所律师不发表意见。 新疆天阳律师事务所（以下简称"本所"）接受光正眼科医院集团股份有限 公司（以下简称"光正眼科" ...

激励对象名单的审核意见及公示情况说明 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 光正眼科医院集团股份有限公司 证券代码：002524 证券简称：光正眼科 公告编号：2023-074 光正眼科医院集团股份有限公司 监事会关于2023年限制性股票激励计划首次授予 1.公示内容：2023 年限制性股票激励计划（以下简称"本激励计划"）首 次授予部分激励对象的姓名和职务。 2.公示时间：2023 年 8 月 28 日至 2023 年 9 月 6 日。 3.公示方式：公司内部OA系统、公司内部办公软件。 4.反馈方式：在公示期限内，公司员工可通过电话、邮件及当面反馈等方式 向监事会进行反馈，公司监事会对相关反馈进行记录。 5.公示结果：截至 2023 年 9 月 6 日公示期满，监事会收到 5 名拟激励对象 的反馈，经查实，因输入有误，导致 5 名拟激励对象的姓名与其身份证登记的姓 光正眼科医院集团股份有限公司 名不一致，现监事会对有误内容更正如下: | 拟激励对象姓名（更正前） | 拟激励对象姓名（更正后） | | --- | --- | | 卓剑锋 | 卓建锋 ...

Group 1: Company Overview and Financial Performance - Guangzheng Eye Hospital Group operates 14 eye hospitals and 3 clinics across major cities, achieving a revenue of 5.46 billion RMB in the first half of 2023, a year-on-year increase of 60% [1][2] - The net profit for the first half of 2023 was 51.7 million RMB, with the ophthalmology segment showing a net profit of 19.75 million RMB, indicating a reduction in losses of 7.18 million RMB [1][2] - The company aims for a revenue target of 1.138 billion RMB for the full year 2023, with a net profit target of 38.56 million RMB [5][6] Group 2: Business Segments and Growth Strategies - The cataract segment generated 1.52 billion RMB in revenue in the first half of 2023, a 159% increase year-on-year, with high-end lens surgeries accounting for 77% of the procedures [2][3] - The refractive surgery segment accounted for 40% of the ophthalmology revenue, with a significant shift in business focus from cataract to refractive surgeries since the acquisition of New Vision Eye Hospital [2][3] - The company has established six major business divisions to enhance operational efficiency and replicate successful practices across different regions [2][3] Group 3: Market Trends and Future Outlook - The cataract market is expected to grow at an annual rate of 15-20% over the next two years, driven by an increasing prevalence of cataracts among the elderly population [2][3] - The company plans to expand its presence in the Yangtze River Delta region and replicate successful business models from Shanghai and Wuxi in other areas [4][5] - The average price for refractive surgeries has increased, with ICL surgeries making up approximately 25% of the total, reflecting a 4 percentage point increase from the previous year [2][3] Group 4: Operational Efficiency and Cost Management - The gross margin for cataract surgeries improved to 47.82%, a 19 percentage point increase year-on-year, while the refractive surgery gross margin reached 45.61%, up by 10.9 percentage points [2][3] - The sales expense ratio for the first half of 2023 was 16%, a decrease compared to the previous year, indicating improved operational efficiency [3][4] - The company is focusing on internal talent development through partnerships with universities to ensure a steady supply of qualified professionals [4][5] Group 5: Corporate Social Responsibility and Community Engagement - Guangzheng actively participates in social responsibility initiatives, including recent eye health screenings in Tibet for students and the elderly [5][6] - The company has established a strategic partnership with Jiangnan University to enhance its clinical data capabilities and improve service delivery [4][5]

Financial Performance - In the first half of 2023, the company achieved a revenue of 546 million RMB, representing a year-on-year growth of 60% [3] - The ophthalmology segment generated a revenue of 414 million RMB, with a year-on-year increase of 73% [3] - The net profit for the first half of 2023 was 5.17 million RMB, a significant improvement from a loss of 68.85 million RMB in the previous year [3] - The gross profit margin for cataract surgeries was 47.82%, up by 19 percentage points year-on-year, while the refractive surgery margin was 45.61%, an increase of 10.9 percentage points [3] Business Transformation - The company has shifted its focus from predominantly cataract surgeries to a balanced approach that includes refractive surgeries, with refractive income now accounting for 40% of the ophthalmology segment [3] - The cataract revenue for the first half of 2023 reached 152 million RMB, a 159% increase year-on-year, with high-end lens surgeries making up 77% of the total [3] - The company has established six major business divisions to enhance operational efficiency and promote healthy development across various disciplines [4] Strategic Initiatives - The company has formed partnerships with academic institutions, such as Fudan University and Jiangnan University, to advance research and development in ophthalmology [4] - A digital hospital initiative is underway, expanding the use of PACS systems and enhancing the application of AI technologies in management [4] - The company is implementing a stock repurchase plan aimed at incentivizing core talent, with plans to grant 9.1999 million restricted stock units to 289 key personnel [4] Market Outlook - The company anticipates a growth rate of 15%-20% in the ophthalmology sector, aligning with industry trends [6] - Expansion plans include both organic growth and acquisitions, with a target of increasing the number of hospitals to around 30 within three years [7] - The company is focusing on enhancing its presence in key urban areas, particularly in the Yangtze River Delta and Chengdu-Chongqing regions [8] Challenges and Responses - The company faces challenges in transitioning its business model to consumer healthcare, necessitating internal training and the establishment of dedicated teams [6] - There is a noted increase in competition within the refractive surgery market, prompting the company to emphasize service quality and operational excellence [7]

Financial Performance - The company's operating revenue for the first half of 2023 was ¥546,407,836.66, representing a 60.08% increase compared to ¥341,335,674.68 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was ¥5,172,240.93, a significant turnaround from a loss of ¥63,676,829.86 in the previous year, marking an increase of 108.12%[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥4,078,548.93, compared to a loss of ¥64,961,746.47 last year, reflecting a 106.28% improvement[19]. - The basic earnings per share increased to ¥0.01 from a loss of ¥0.12, showing an increase of 108.33%[19]. - The total assets at the end of the reporting period were ¥1,564,940,965.80, a slight increase of 0.48% from ¥1,557,450,440.86 at the end of the previous year[19]. - The net assets attributable to shareholders of the listed company rose to ¥288,094,604.86, up 5.51% from ¥273,057,664.03 at the end of the previous year[19]. - The net cash flow from operating activities was ¥1,570,850.18, a decrease of 88.78% compared to ¥13,999,221.12 in the same period last year[19]. - The weighted average return on net assets improved to 1.89% from -20.63% in the previous year, an increase of 22.52%[19]. - The gross profit margin for the medical sector improved to 40.53%, up 13.11% from the previous year[45]. - The company reported a total revenue of 6,144 million CNY for the first half of 2023, reflecting a year-on-year increase of 15%[112]. Operational Strategy - The company operates 14 specialized ophthalmology hospitals and 3 optometry clinics across 10 major cities in China, providing comprehensive eye care services[27]. - The company has established a national chain network with all hospitals being designated medical insurance institutions, enhancing its brand reputation and service quality[27]. - The company focuses on major urban markets, particularly in the Yangtze River Delta, Beijing-Tianjin-Hebei, Pearl River Delta, Jiaodong Peninsula, and Chengdu-Chongqing regions, strengthening its competitive position[30]. - The company has implemented a unified brand management strategy while allowing localized marketing measures to enhance brand image and service quality[28]. - The company has developed a standardized and systematic management model for its ophthalmology services, which has led to significant market share in local areas[32]. - The company has seen a growing number of hospitals capturing the largest market share in outpatient volume, surgical volume, and revenue in their respective regions[30]. - The company emphasizes a dual-track procurement strategy to optimize purchasing efficiency and meet the needs of its hospitals[28]. - The company aims to expand its network further in key urban areas, with recent openings of new clinics in Shanghai to enhance service accessibility[32]. - The company is implementing a regional strategy targeting major urban clusters, including the Yangtze River Delta and the Pearl River Delta, to enhance market presence[61]. Research and Development - In March 2023, the company established the "Ophthalmic Health Innovation Technology Joint Laboratory" with Fudan University, enhancing its academic and research capabilities[33]. - The company has formed strategic partnerships with institutions like Jiangnan University to advance research on biomarkers for eye diseases, establishing the Jiangnan University New Vision Ophthalmology Research Center[33]. - The company has a strong focus on R&D in assembly-type steel structures, contributing to its competitive edge in the construction industry[31]. - Research and development investments increased by 30% year-on-year, focusing on advanced surgical technologies[112]. - The company has initiated research and development for new products aimed at improving patient care and operational efficiency[179]. Talent and Human Resources - The company has implemented a competitive compensation system and a restricted stock incentive plan to enhance talent retention and motivation[38]. - The company has organized 49 sessions of difficult case discussions to promote knowledge sharing and rapid growth among young doctors[33]. - The company has established a national cataract training program to address the shortage of ophthalmic talent in China[33]. - The company has a robust talent acquisition strategy, attracting top ophthalmology experts and enhancing its core expert team[36]. - The company has established a talent reserve mechanism combining "internal training + external introduction" to strengthen its medical team and management capabilities[62]. Market Expansion and Future Outlook - The company plans to continue leveraging its brand and service advantages to accelerate business recovery and growth in the ophthalmic market[41]. - The company has set a performance guidance for the next quarter, expecting a revenue growth of approximately 10% year-over-year[179]. - The company is exploring potential mergers and acquisitions to strengthen its market position and expand its service capabilities[178]. - The company has outlined a strategic plan for market expansion, targeting key urban areas with high demand for eye care services[117]. - The company is actively pursuing strategic acquisitions to bolster its market position and enhance its service offerings[176]. Compliance and Governance - The company emphasizes the protection of shareholder and creditor rights, ensuring compliance with relevant laws and regulations, and timely disclosure of major events[78]. - The company faced an administrative penalty of RMB 350,000 for not obtaining a pollution discharge permit, but this did not have a significant impact on operations[77]. - The company has not experienced any major litigation or arbitration matters during the reporting period[95]. - The company has committed to avoiding competition with its subsidiaries and related entities[89]. - The company has not reported any bankruptcy restructuring matters during the reporting period[94]. Financial Management and Investments - The company has established a robust service system that integrates diagnosis, nursing, and customer service to enhance patient care[29]. - The company has a stable supplier and management system for key raw materials, including ophthalmic crystal materials and steel plates, but faces risks from potential price increases[62]. - The company plans to optimize production processes and conduct technological innovations to mitigate the adverse effects of rising raw material prices[62]. - The company has provided guarantees for its subsidiaries, with a total guarantee amount of 2,040.8 million RMB for Shanghai New Vision Eye Hospital[111]. - The company has a commitment to maintaining financial transparency and accountability in its leasing and guarantee activities[111]. Shareholder Information - The company held its annual general meeting with 26.75% investor participation, approving various financial reports and budget proposals[65]. - The total number of ordinary shareholders at the end of the reporting period was 49,906[137]. - The largest shareholder, Guangzheng Investment Co., Ltd., holds 25.06% of the shares, totaling 129,168,708 shares[137]. - The company reported a total of 6,063,600 restricted shares held by executives and other shareholders[135]. - The company plans to repurchase and cancel 814,400 shares of restricted stock due to reasons such as employee departures and performance evaluations not meeting unlock requirements, reducing total shares from 515,366,420 to 514,552,020[195].

2．本次会议召集人：公司第五届董事会 光正眼科医院集团股份有限公司 证券代码：002524 证券简称：光正眼科 公告编号：2023-073 光正眼科医院集团股份有限公司 关于召开 2023 年度第三次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 光正眼科医院集团股份有限公司（以下简称"公司"）第五届董事会第十九 次会议决定，于 2023 年 9 月 11 日召开公司 2023 年度第三次临时股东大会，现 将会议相关事项公告如下： 一、召开会议基本情况 1．本次会议届次：2023 年度第三次临时股东大会 3．本次会议召开的合法、合规性：公司于 2023 年 8 月 23 日召开第五届董 事会第十九次会议，审议通过了《关于提请召开 2023 年度第三次临时股东大会 的议案》，本次会议召开符合有关法律、行政法规、部门规章、规范性文件和《公 司章程》等的有关规定。 4．会议召开的日期、时间： 现场会议时间为：2023 年 9 月 11 日（星期一）下午 15:00 网络投票时间为：2023 年 9 月 11 日。其中：通过深圳证券交易所交易系统 ...

| 15 | 上市公司全部在有效期内的股权激励计划所涉及的标的股票总数 | 是 | | --- | --- | --- | | | 累计是否未超过公司股本总额的 10% | | | 16 | 单一激励对象通过全部在有效期内的股权激励计划累计获授股 | 是 | | | 票是否未超过公司股本总额的 1% | | | 17 | 激励对象预留权益比例是否未超过本次股权激励计划拟授予权 | 是 | | | 益数量的 20% | | | 18 | 激励对象为董事、高管的，股权激励计划草案是否已列明其姓 | 是 | | | 名、职务、获授数量 | | | 19 | 激励对象为董事、高管的，是否设立绩效考核指标作为激励对 | 是 | | | 象行使权益的条件 | | | 20 | 股权激励计划的有效期从首次授予权益日起是否未超过 10 年 | 是 | | 21 | 股权激励计划草案是否由薪酬与考核委员会负责拟定 | 是 | | | 股权激励计划披露完整性要求 | | | 22 | 股权激励计划所规定事项是否完整 | 是 | | | （1）对照《股权激励管理办法》的相关规定，逐条说明是否存 | 是 | | | 在上市公司不得实 ...